Now a newer class of medications used to treat type 2 diabetes has gained attention because of their impressive weight-loss results in many cases, 10% to 20% of a person's body weight
Lixisenatide, a structurally modified derivative of exendin-4, addresses some of these limitations by offering a longer half-life of approximately 3 h, thereby permitting once-daily dosing (Leon et al., 2017)
Catering to the GLP-1 patient population As GLP-1 medications surge in popularity for the overweight and obese population, as well as for those with diabetes and other health conditions, an opportunity has opened up in the market
16 Surprisingly, replacing GIP Lys 16 with Ala promotes the insulinotropic effect of GIP
The abdomen is typically the best starting site at higher body weights
or with a BMI of 27 or more and pre-diabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease